EN DE
Watch SBC Medical Group Holdings Incorporated for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SBC Medical Group Holdings Incorporated (SBC) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of SBC Medical Group Holdings Incorporated stock $7.18, price $5.04, upside +42.5%, quality 65 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials US

SM SBC Medical Group Holdings Incorporated logo Some data Nov 7, 2026

SBC Medical Group Holdings Incorporated

SBC · US
Meets all rules

The stock costs 30% less than our calculation considers fair.

Fair value $7.18 · Undervalued
Quality 65/100
Highly profitable · 28.0% net margin (TTM)
Low debt
Generates free cash flow
Ranks above peers (12/14)
Upbeat coverage
Even on cautious assumptions the value is 8% above the price ($5.44).
Mixed Growth
Wide moat 83/100 · thin data
Some data
⚠ Small free float
Watch SBC Medical Group Holdings Incorporated for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$16.00 $2.87 Fair Value $7.18 Sep 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

49‑month range $2.87 – $16.00 · fair‑value band $5.44 – $9.07 · the $5.04 price screens below the $7.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow SBC Medical Group Holdings in your weekly email

Every Wednesday you see whether SBC Medical Group Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore.

Show moreShow less

The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement.

It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers.

In addition, the company offers surgical and non-surgical surgeries that include breast augmentation; liposuction; rejuvenation treatments, such as treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods.

Further, it owns and operates treatment centers under the SBC brand. SBC Medical Group Holdings Incorporated was founded in 2000 and is headquartered in Irvine, California.

Stock analysis

SBC Medical Group Holdings Incorporated (SBC) currently trades at $5.04, while our model-based Fair Value estimate is $7.18, implying the stock looks roughly 30% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $9.37 per share, and 17 of the 22 models we run sit above the $5.04 price.

Bear case: the Asset-Based group reads lowest at $0.9600, and 5 of the 22 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $5.44 (bear) to $9.07 (bull), the price of $5.04 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Industrials sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

SBC Medical Group Holdings Incorporated reported revenue of $174M in FY2025 versus $174M in FY2022, a compound −0.1%/yr. Reported net income was $51.0M in FY2025, compounding +100.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.

Key figures

Market cap $517M Small · P/E ratio 10.5 · P/S ratio 2.95 · EPS (TTM) $0.4800 · Net margin 28.0% · Return on equity 18.9% · Return on assets (EBIT) 20.1% (4-year average) · Operating margin 38.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 83 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 76% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −7% fair-value upside, at 42%, SBC screens cheaper than that median.

Fair Value models

Bear $5.44 Fair Value $7.18 Bull $9.07
Price $5.04 · Upside +42.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.4116 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $4.45 $5.55 $7.50 78
Growth DCF $4.57 $5.63 $7.35 77
Owner Earnings $4.66 $5.84 $7.92 75
All 22 models by family
DCF Models
FCF DCF $4.45 $5.55 $7.50 78
Owner Earnings $4.66 $5.84 $7.92 75
5Y Revenue Exit $4.49 $5.98 $8.15 70
5Y EBITDA Exit $6.19 $8.92 $12.54 72
5Y P/E Exit $6.70 $9.81 $13.51 68
10Y Revenue Exit $4.36 $5.44 $6.59 65
10Y EBITDA Exit $5.44 $7.18 $9.07 67
10Y P/E Exit $5.74 $7.71 $9.61 62
Earnings-Based
Graham-Dodd $3.37 $4.12 $4.64 65
EPV $4.38 $4.85 $5.25 74
Multiples
P/E Multiple $8.18 $10.91 $13.63 63
P/S Multiple $4.43 $5.91 $7.39 58
P/B Multiple $6.07 $8.10 $10.12 55
EV/EBIT $9.46 $12.25 $15.03 66
EV/EBITDA $8.25 $10.64 $13.03 67
EV/Revenue $4.64 $6.15 $7.67 54
Asset-Based
NCAV (Graham) $0.6400 $0.9600 $1.20 55
Growth DCF
Growth DCF $4.57 $5.63 $7.35 77
Rev-Margin DCF $4.49 $6.06 $7.98 71
Economic Profit
Residual Income $2.85 $3.36 $4.45 68
ROIC Compounder $4.38 $4.96 $5.51 69
Growth Earnings
Growth-Adj P/E $5.77 $8.24 $10.71 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 65/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 68
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 35
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 88
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleYoshiyuki AikawaChairman and CEO, Director, 10% owner3× since Mar 6, 2026: 7,987,900 shares, avg. $2.52$20.1MApr 28, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.9%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 39%

Growth Forecast

Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −3.5% a year for the price and +6.4% for the forecasts.
Forecast 2026 (sales)+10.0%
Forecast 2027 (sales)+10.1%
Projected 2028 (sales)+9.1%
Projected 2029 (sales)+8.1%
Projected 2030 (sales)+7.1%

Watch SBC, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (62 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare SBC Medical Group Holdings Incorporated with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Consulting Services · 74 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 65 · Above median
Fair Value upside +42.5% · Above median
Profitability
Return on equity (12 months) 18.9% · Top 25%
Return on assets 13.4% · Top 25%
Net margin (12 months) 28.0% · Top 25%
Operating margin (12 months) 38.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 13.4% · Top 25%
Balance sheet
Debt / equity 0.14× · Below median

Valuation Multiplesvs Consulting Services median · lower = cheaper

P/E (12 months) 10.5× · Cheapest 25%
P/B 2.08× · Cheaper than median
P/S (12 months) 2.95× · Priciest 25%
Price / free cash flow (fiscal year) 14.1× · Cheaper than median
EV/EBITDA 5.6× · Cheaper than median
PEG 1.93× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)90 · sector 45
FUTURE (revenue growth)67 · sector 18
PAST (return on equity)76 · sector 35
HEALTH (low debt)93 · sector 89
DIVIDEND (yield)0 · sector 63

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Consulting Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Booz Allen Hamilton Holding BAH $85.35 $159.98 +87% vs SBC
ICF International, Inc ICFI $79.68 $99.21 +25% vs SBC
Huron Consulting Group HURN $166.82 $183.50 +10% vs SBC
Bureau Veritas SA BVI €29.95 €27.88 −7% vs SBC
FTI Consulting, Inc FCN $195.71 $182.15 −7% vs SBC
DKSH Holding DKSH CHF 76.70 CHF 65.52 −15% vs SBC
Verisk Analytics, Inc VRSK $204.59 $148.69 −27% vs SBC
SGS SA SGSN CHF 101.95 CHF 70.45 −31% vs SBC
Equifax Inc EFX $189.59 $109.01 −43% vs SBC
ALS Limited ALQ A$20.80 A$11.18 −46% vs SBC

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SBC Medical Group Holdings Incorporated: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SBC Medical Group Holdings Incorporated Fair Value". https://www.fairvalue-calculator.com/stock/SBC

Frequently asked questions

Is SBC Medical Group Holdings Incorporated (SBC) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $7.18 versus a price of $5.04, about +42% upside (undervalued).
What is the fair value of SBC?
Our model-based fair value for SBC Medical Group Holdings Incorporated is $7.18 (as of Nov 7, 2026), built from audited fundamentals. The current price: $5.04.
What is the quality score of SBC?
SBC Medical Group Holdings Incorporated has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SBC Medical Group Holdings Incorporated (SBC)?
Our model-based price target is the fair value of $7.18 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario $5.44, optimistic scenario $9.07. It is a calculation from audited fundamentals, not an analyst target.
What is the SBC Medical Group Holdings Incorporated stock forecast for 2026?
Our models put fair value at $7.18, about +42% upside versus a price of $5.04 (undervalued). Cautious scenario $5.44, optimistic scenario $9.07. The calculation is refreshed regularly with new filings.
What is the revenue of SBC Medical Group Holdings Incorporated (SBC)?
SBC Medical Group Holdings Incorporated reported trailing-twelve-month revenue of about $175M (latest available figure, as of Nov 7, 2026).
What growth is priced into SBC Medical Group Holdings Incorporated (SBC)?
For today's price to be fair in a discounted-cash-flow model, SBC Medical Group Holdings Incorporated would have to grow free cash flow by -1.2 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew -0.1 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of SBC use?
Our models discount SBC Medical Group Holdings Incorporated at 9.9 %: a base by market capitalisation (small), damped by beta 0.52, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SBC Medical Group Holdings Incorporated that is -1.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has SBC Medical Group Holdings Incorporated (SBC) delivered so far?
Over the past 3 years revenue at SBC Medical Group Holdings Incorporated grew -0.1 % a year. The price currently implies free-cash-flow growth of -1.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SBC Medical Group Holdings Incorporated (SBC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into SBC Medical Group Holdings Incorporated (-1.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SBC Medical Group Holdings Incorporated (SBC)?
The free-cash-flow yield on the price is 7.07 %: that much free cash flow SBC Medical Group Holdings Incorporated produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SBC Medical Group Holdings Incorporated (SBC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SBC Medical Group Holdings Incorporated it is $7.18 per share (as of Nov 7, 2026), against a price of $5.04. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SBC Medical Group Holdings Incorporated stock overvalued or undervalued in 2026?
As of Nov 7, 2026, SBC trades below its calculated fair value: price $5.04, fair value $7.18, a gap of about +42% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SBC?
No. The price is what the market pays today ($5.04); the fair value is what the company's own numbers justify ($7.18). For SBC Medical Group Holdings Incorporated the two are $2.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is SBC Medical Group Holdings Incorporated worth?
The market values SBC Medical Group Holdings Incorporated at about $517M (market capitalisation, as of Nov 7, 2026). Per share that is $5.04; our models calculate a fair value of $7.18 per share.
What do the bullish and bearish scenarios say about SBC?
Our models span a range for SBC Medical Group Holdings Incorporated: cautious scenario $5.44, base $7.18, optimistic $9.07 per share (as of Nov 7, 2026, price $5.04). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SBC?
SBC Medical Group Holdings Incorporated trades at a price-to-earnings ratio of 10.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.18 is built from several models across several years. Other multiples: PEG 1.9, P/B 2.1, P/S 3.0, EV/EBITDA 5.6.
What is the PEG ratio of SBC?
The PEG ratio of SBC Medical Group Holdings Incorporated is 1.93 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of SBC Medical Group Holdings Incorporated (SBC)?
Balance-sheet figures for SBC Medical Group Holdings Incorporated (as of Nov 7, 2026): return on equity 18.9%, debt of 0.14 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is SBC from its 52-week high?
SBC Medical Group Holdings Incorporated trades at $5.04, about 11% below its 52-week high of $5.69 and 76% above the low of $2.87 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.18 is for.
Which stocks are comparable to SBC Medical Group Holdings Incorporated?
From the same area (Industrials) we also value Verisk Analytics, Inc, SGS SA, Equifax Inc, Bureau Veritas SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SBC Medical Group Holdings Incorporated stock attractive at the current price?
The data as of Nov 7, 2026: price $5.04, calculated fair value $7.18 (+42%), Quality Score 65/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SBC calculated?
We run SBC Medical Group Holdings Incorporated through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.18 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SBC Medical Group Holdings Incorporated currently trades 30% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SBC Medical Group Holdings Incorporated (SBC)?
The closing price on Nov 6, 2026 was $5.04. Our model-based fair value is $7.18, about +42% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SBC Medical Group Holdings Incorporated right now?
The price is below even our cautious bear case ($5.44). The market is more pessimistic than our downside scenario. Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of SBC Medical Group Holdings Incorporated

How large is the market capitalisation of SBC Medical Group Holdings Incorporated (SBC)?
The market capitalisation of SBC Medical Group Holdings Incorporated is $517M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SBC Medical Group Holdings Incorporated (SBC)?
The price-to-sales ratio of SBC Medical Group Holdings Incorporated is 2.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SBC Medical Group Holdings Incorporated (SBC)?
Earnings per share at SBC Medical Group Holdings Incorporated are $0.4800 (price ÷ EPS = P/E 10.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SBC Medical Group Holdings Incorporated (SBC)?
The net margin of SBC Medical Group Holdings Incorporated is 28.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SBC Medical Group Holdings Incorporated (SBC)?
The return on equity (ROE) of SBC Medical Group Holdings Incorporated is 18.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SBC Medical Group Holdings Incorporated (SBC)?
On an EBIT basis the return on assets of SBC Medical Group Holdings Incorporated is 20.1% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SBC Medical Group Holdings Incorporated (SBC)?
The operating margin of SBC Medical Group Holdings Incorporated is 38.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SBC Medical Group Holdings Incorporated (SBC)?
Revenue at SBC Medical Group Holdings Incorporated is growing +13.4% versus a year earlier (3y avg −0.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SBC Medical Group Holdings Incorporated (SBC)?
Earnings per share at SBC Medical Group Holdings Incorporated are growing +339% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SBC Medical Group Holdings Incorporated (SBC) hold?
SBC Medical Group Holdings Incorporated holds more cash than debt, $112M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SBC Medical Group Holdings Incorporated in the live analysis

One click puts SBC Medical Group Holdings Incorporated on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.